Reports Q1 revenue $146.81M, consensus $141.2M. “There were a record number of new Korlym(R) prescribers in the first quarter and a record number of patients receiving Korlym. Physicians are increasingly aware that hypercortisolism is much more prevalent than was previously assumed, so they are screening more patients for the disorder,” said Joseph K. Belanoff, Corcept’s Chief Executive Officer. “When Korlym is prescribed, we use the expertise and infrastructure that we have developed and refined over many years to support physicians and patients. This additional care helps create a life-changing impact for patients who receive Korlym treatment.”
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Therapeutics Reveals Q1 2024 Financial Results and Update
- Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
- Corcept Therapeutics completes enrollment in Phase 4 CATALYST trial
- Is CORT a Buy, Before Earnings?
- Biotech Alert: Searches spiking for these stocks today